List of Excipients in API GEFITINIB
✉ Email this page to a colleague
Excipients in NDA-approved (novel) drugs containing GEFITINIB
Company | Tradename | Ingredient | NDC | Excipient | Potential Generic Entry |
---|---|---|---|---|---|
AstraZeneca Pharmaceuticals LP | IRESSA | gefitinib | 0310-0482 | CELLULOSE, MICROCRYSTALLINE | |
AstraZeneca Pharmaceuticals LP | IRESSA | gefitinib | 0310-0482 | CROSCARMELLOSE SODIUM | |
AstraZeneca Pharmaceuticals LP | IRESSA | gefitinib | 0310-0482 | FERRIC OXIDE RED | |
AstraZeneca Pharmaceuticals LP | IRESSA | gefitinib | 0310-0482 | FERRIC OXIDE YELLOW | |
AstraZeneca Pharmaceuticals LP | IRESSA | gefitinib | 0310-0482 | HYPROMELLOSE | |
AstraZeneca Pharmaceuticals LP | IRESSA | gefitinib | 0310-0482 | LACTOSE MONOHYDRATE | |
AstraZeneca Pharmaceuticals LP | IRESSA | gefitinib | 0310-0482 | MAGNESIUM STEARATE | |
>Company | >Tradename | >Ingredient | >NDC | >Excipient | >Potential Generic Entry |
Excipients in ANDA-approved (generic) drugs containing GEFITINIB
Detailed excipient profiles for GEFITINIB
Excipient focus: CELLULOSE, MICROCRYSTALLINE
GEFITINIB drug variants containing CELLULOSE, MICROCRYSTALLINE
Company | Ingredient | NDC |
---|---|---|
AstraZeneca Pharmaceuticals LP | gefitinib | 0310-0482 |
Teva Pharmaceuticals Inc | gefitinib | 0480-4053 |
Ingenus Pharmaceuticals LLC | gefitinib | 50742-366 |
Qilu Pharmaceutical Co Ltd | gefitinib | 67184-0531 |
>Company | >Ingredient | >NDC |
GEFITINIB drug variants not containing CELLULOSE, MICROCRYSTALLINE
Company | Ingredient | NDC |
---|---|---|
Apotex Corp | gefitinib | 60505-4512 |
Natco Pharma USA LLC | gefitinib | 69339-168 |
>Company | >Ingredient | >NDC |
Excipient focus: CROSCARMELLOSE SODIUM
GEFITINIB drug variants containing CROSCARMELLOSE SODIUM
Company | Ingredient | NDC |
---|---|---|
AstraZeneca Pharmaceuticals LP | gefitinib | 0310-0482 |
Teva Pharmaceuticals Inc | gefitinib | 0480-4053 |
Ingenus Pharmaceuticals LLC | gefitinib | 50742-366 |
Qilu Pharmaceutical Co Ltd | gefitinib | 67184-0531 |
Natco Pharma USA LLC | gefitinib | 69339-168 |
>Company | >Ingredient | >NDC |
GEFITINIB drug variants not containing CROSCARMELLOSE SODIUM
Company | Ingredient | NDC |
---|---|---|
Apotex Corp | gefitinib | 60505-4512 |
>Company | >Ingredient | >NDC |
Excipient focus: CROSPOVIDONE
GEFITINIB drug variants containing CROSPOVIDONE
Company | Ingredient | NDC |
---|---|---|
Apotex Corp | gefitinib | 60505-4512 |
>Company | >Ingredient | >NDC |
GEFITINIB drug variants not containing CROSPOVIDONE
Company | Ingredient | NDC |
---|---|---|
AstraZeneca Pharmaceuticals LP | gefitinib | 0310-0482 |
Teva Pharmaceuticals Inc | gefitinib | 0480-4053 |
Ingenus Pharmaceuticals LLC | gefitinib | 50742-366 |
Qilu Pharmaceutical Co Ltd | gefitinib | 67184-0531 |
Natco Pharma USA LLC | gefitinib | 69339-168 |
>Company | >Ingredient | >NDC |
Excipient focus: DIMETHYLAMINOETHYL METHACRYLATE - BUTYL METHACRYLATE - METHYL METHACRYLATE COPOLYMER
GEFITINIB drug variants containing DIMETHYLAMINOETHYL METHACRYLATE - BUTYL METHACRYLATE - METHYL METHACRYLATE COPOLYMER
Company | Ingredient | NDC |
---|---|---|
Apotex Corp | gefitinib | 60505-4512 |
>Company | >Ingredient | >NDC |
GEFITINIB drug variants not containing DIMETHYLAMINOETHYL METHACRYLATE - BUTYL METHACRYLATE - METHYL METHACRYLATE COPOLYMER
Company | Ingredient | NDC |
---|---|---|
AstraZeneca Pharmaceuticals LP | gefitinib | 0310-0482 |
Teva Pharmaceuticals Inc | gefitinib | 0480-4053 |
Ingenus Pharmaceuticals LLC | gefitinib | 50742-366 |
Qilu Pharmaceutical Co Ltd | gefitinib | 67184-0531 |
Natco Pharma USA LLC | gefitinib | 69339-168 |
>Company | >Ingredient | >NDC |
Excipient focus: FERRIC OXIDE RED
GEFITINIB drug variants containing FERRIC OXIDE RED
Company | Ingredient | NDC |
---|---|---|
AstraZeneca Pharmaceuticals LP | gefitinib | 0310-0482 |
Teva Pharmaceuticals Inc | gefitinib | 0480-4053 |
Ingenus Pharmaceuticals LLC | gefitinib | 50742-366 |
Apotex Corp | gefitinib | 60505-4512 |
Qilu Pharmaceutical Co Ltd | gefitinib | 67184-0531 |
Natco Pharma USA LLC | gefitinib | 69339-168 |
>Company | >Ingredient | >NDC |
GEFITINIB drug variants not containing FERRIC OXIDE RED
Company | Ingredient | NDC |
---|---|---|
>Company | >Ingredient | >NDC |
Excipient focus: FERRIC OXIDE YELLOW
GEFITINIB drug variants containing FERRIC OXIDE YELLOW
Company | Ingredient | NDC |
---|---|---|
AstraZeneca Pharmaceuticals LP | gefitinib | 0310-0482 |
Teva Pharmaceuticals Inc | gefitinib | 0480-4053 |
Ingenus Pharmaceuticals LLC | gefitinib | 50742-366 |
Qilu Pharmaceutical Co Ltd | gefitinib | 67184-0531 |
Natco Pharma USA LLC | gefitinib | 69339-168 |
>Company | >Ingredient | >NDC |
GEFITINIB drug variants not containing FERRIC OXIDE YELLOW
Company | Ingredient | NDC |
---|---|---|
Apotex Corp | gefitinib | 60505-4512 |
>Company | >Ingredient | >NDC |
Excipient focus: FERROSOFERRIC OXIDE
GEFITINIB drug variants containing FERROSOFERRIC OXIDE
Company | Ingredient | NDC |
---|---|---|
Ingenus Pharmaceuticals LLC | gefitinib | 50742-366 |
Qilu Pharmaceutical Co Ltd | gefitinib | 67184-0531 |
>Company | >Ingredient | >NDC |
GEFITINIB drug variants not containing FERROSOFERRIC OXIDE
Company | Ingredient | NDC |
---|---|---|
AstraZeneca Pharmaceuticals LP | gefitinib | 0310-0482 |
Teva Pharmaceuticals Inc | gefitinib | 0480-4053 |
Apotex Corp | gefitinib | 60505-4512 |
Natco Pharma USA LLC | gefitinib | 69339-168 |
>Company | >Ingredient | >NDC |
Excipient focus: HYPROMELLOSE
GEFITINIB drug variants containing HYPROMELLOSE
Company | Ingredient | NDC |
---|---|---|
AstraZeneca Pharmaceuticals LP | gefitinib | 0310-0482 |
>Company | >Ingredient | >NDC |
GEFITINIB drug variants not containing HYPROMELLOSE
Company | Ingredient | NDC |
---|---|---|
Teva Pharmaceuticals Inc | gefitinib | 0480-4053 |
Ingenus Pharmaceuticals LLC | gefitinib | 50742-366 |
Apotex Corp | gefitinib | 60505-4512 |
Qilu Pharmaceutical Co Ltd | gefitinib | 67184-0531 |
Natco Pharma USA LLC | gefitinib | 69339-168 |
>Company | >Ingredient | >NDC |
Excipient focus: LACTOSE MONOHYDRATE
GEFITINIB drug variants containing LACTOSE MONOHYDRATE
Company | Ingredient | NDC |
---|---|---|
AstraZeneca Pharmaceuticals LP | gefitinib | 0310-0482 |
Teva Pharmaceuticals Inc | gefitinib | 0480-4053 |
Ingenus Pharmaceuticals LLC | gefitinib | 50742-366 |
Qilu Pharmaceutical Co Ltd | gefitinib | 67184-0531 |
Natco Pharma USA LLC | gefitinib | 69339-168 |
>Company | >Ingredient | >NDC |
GEFITINIB drug variants not containing LACTOSE MONOHYDRATE
Company | Ingredient | NDC |
---|---|---|
Apotex Corp | gefitinib | 60505-4512 |
>Company | >Ingredient | >NDC |
Excipient focus: MAGNESIUM STEARATE
GEFITINIB drug variants containing MAGNESIUM STEARATE
Company | Ingredient | NDC |
---|---|---|
AstraZeneca Pharmaceuticals LP | gefitinib | 0310-0482 |
Teva Pharmaceuticals Inc | gefitinib | 0480-4053 |
Ingenus Pharmaceuticals LLC | gefitinib | 50742-366 |
Apotex Corp | gefitinib | 60505-4512 |
Qilu Pharmaceutical Co Ltd | gefitinib | 67184-0531 |
Natco Pharma USA LLC | gefitinib | 69339-168 |
>Company | >Ingredient | >NDC |
GEFITINIB drug variants not containing MAGNESIUM STEARATE
Company | Ingredient | NDC |
---|---|---|
>Company | >Ingredient | >NDC |
Excipient focus: MICROCRYSTALLINE CELLULOSE 101
GEFITINIB drug variants containing MICROCRYSTALLINE CELLULOSE 101
Company | Ingredient | NDC |
---|---|---|
Natco Pharma USA LLC | gefitinib | 69339-168 |
>Company | >Ingredient | >NDC |
GEFITINIB drug variants not containing MICROCRYSTALLINE CELLULOSE 101
Company | Ingredient | NDC |
---|---|---|
AstraZeneca Pharmaceuticals LP | gefitinib | 0310-0482 |
Teva Pharmaceuticals Inc | gefitinib | 0480-4053 |
Ingenus Pharmaceuticals LLC | gefitinib | 50742-366 |
Apotex Corp | gefitinib | 60505-4512 |
Qilu Pharmaceutical Co Ltd | gefitinib | 67184-0531 |
>Company | >Ingredient | >NDC |
Excipient focus: MICROCRYSTALLINE CELLULOSE 102
GEFITINIB drug variants containing MICROCRYSTALLINE CELLULOSE 102
Company | Ingredient | NDC |
---|---|---|
Natco Pharma USA LLC | gefitinib | 69339-168 |
>Company | >Ingredient | >NDC |
GEFITINIB drug variants not containing MICROCRYSTALLINE CELLULOSE 102
Company | Ingredient | NDC |
---|---|---|
AstraZeneca Pharmaceuticals LP | gefitinib | 0310-0482 |
Teva Pharmaceuticals Inc | gefitinib | 0480-4053 |
Ingenus Pharmaceuticals LLC | gefitinib | 50742-366 |
Apotex Corp | gefitinib | 60505-4512 |
Qilu Pharmaceutical Co Ltd | gefitinib | 67184-0531 |
>Company | >Ingredient | >NDC |
Excipient focus: POLYETHYLENE GLYCOL
GEFITINIB drug variants containing POLYETHYLENE GLYCOL
Company | Ingredient | NDC |
---|---|---|
Natco Pharma USA LLC | gefitinib | 69339-168 |
>Company | >Ingredient | >NDC |
GEFITINIB drug variants not containing POLYETHYLENE GLYCOL
Company | Ingredient | NDC |
---|---|---|
AstraZeneca Pharmaceuticals LP | gefitinib | 0310-0482 |
Teva Pharmaceuticals Inc | gefitinib | 0480-4053 |
Ingenus Pharmaceuticals LLC | gefitinib | 50742-366 |
Apotex Corp | gefitinib | 60505-4512 |
Qilu Pharmaceutical Co Ltd | gefitinib | 67184-0531 |
>Company | >Ingredient | >NDC |
Excipient focus: POLYETHYLENE GLYCOL 300
GEFITINIB drug variants containing POLYETHYLENE GLYCOL 300
Company | Ingredient | NDC |
---|---|---|
AstraZeneca Pharmaceuticals LP | gefitinib | 0310-0482 |
>Company | >Ingredient | >NDC |
GEFITINIB drug variants not containing POLYETHYLENE GLYCOL 300
Company | Ingredient | NDC |
---|---|---|
Teva Pharmaceuticals Inc | gefitinib | 0480-4053 |
Ingenus Pharmaceuticals LLC | gefitinib | 50742-366 |
Apotex Corp | gefitinib | 60505-4512 |
Qilu Pharmaceutical Co Ltd | gefitinib | 67184-0531 |
Natco Pharma USA LLC | gefitinib | 69339-168 |
>Company | >Ingredient | >NDC |
Excipient focus: POLYETHYLENE GLYCOL 3350
GEFITINIB drug variants containing POLYETHYLENE GLYCOL 3350
Company | Ingredient | NDC |
---|---|---|
Teva Pharmaceuticals Inc | gefitinib | 0480-4053 |
Ingenus Pharmaceuticals LLC | gefitinib | 50742-366 |
Qilu Pharmaceutical Co Ltd | gefitinib | 67184-0531 |
>Company | >Ingredient | >NDC |
GEFITINIB drug variants not containing POLYETHYLENE GLYCOL 3350
Company | Ingredient | NDC |
---|---|---|
AstraZeneca Pharmaceuticals LP | gefitinib | 0310-0482 |
Apotex Corp | gefitinib | 60505-4512 |
Natco Pharma USA LLC | gefitinib | 69339-168 |
>Company | >Ingredient | >NDC |
Excipient focus: POLYETHYLENE GLYCOL 8000
GEFITINIB drug variants containing POLYETHYLENE GLYCOL 8000
Company | Ingredient | NDC |
---|---|---|
Apotex Corp | gefitinib | 60505-4512 |
>Company | >Ingredient | >NDC |
GEFITINIB drug variants not containing POLYETHYLENE GLYCOL 8000
Company | Ingredient | NDC |
---|---|---|
AstraZeneca Pharmaceuticals LP | gefitinib | 0310-0482 |
Teva Pharmaceuticals Inc | gefitinib | 0480-4053 |
Ingenus Pharmaceuticals LLC | gefitinib | 50742-366 |
Qilu Pharmaceutical Co Ltd | gefitinib | 67184-0531 |
Natco Pharma USA LLC | gefitinib | 69339-168 |
>Company | >Ingredient | >NDC |
Excipient focus: POLYVINYL ALCOHOL
GEFITINIB drug variants containing POLYVINYL ALCOHOL
Company | Ingredient | NDC |
---|---|---|
Teva Pharmaceuticals Inc | gefitinib | 0480-4053 |
Ingenus Pharmaceuticals LLC | gefitinib | 50742-366 |
Apotex Corp | gefitinib | 60505-4512 |
Qilu Pharmaceutical Co Ltd | gefitinib | 67184-0531 |
Natco Pharma USA LLC | gefitinib | 69339-168 |
>Company | >Ingredient | >NDC |
GEFITINIB drug variants not containing POLYVINYL ALCOHOL
Company | Ingredient | NDC |
---|---|---|
AstraZeneca Pharmaceuticals LP | gefitinib | 0310-0482 |
>Company | >Ingredient | >NDC |
Excipient focus: POVIDONE
GEFITINIB drug variants containing POVIDONE
Company | Ingredient | NDC |
---|---|---|
AstraZeneca Pharmaceuticals LP | gefitinib | 0310-0482 |
Teva Pharmaceuticals Inc | gefitinib | 0480-4053 |
>Company | >Ingredient | >NDC |
GEFITINIB drug variants not containing POVIDONE
Company | Ingredient | NDC |
---|---|---|
Ingenus Pharmaceuticals LLC | gefitinib | 50742-366 |
Apotex Corp | gefitinib | 60505-4512 |
Qilu Pharmaceutical Co Ltd | gefitinib | 67184-0531 |
Natco Pharma USA LLC | gefitinib | 69339-168 |
>Company | >Ingredient | >NDC |
Excipient focus: POVIDONE K30
GEFITINIB drug variants containing POVIDONE K30
Company | Ingredient | NDC |
---|---|---|
Ingenus Pharmaceuticals LLC | gefitinib | 50742-366 |
Qilu Pharmaceutical Co Ltd | gefitinib | 67184-0531 |
Natco Pharma USA LLC | gefitinib | 69339-168 |
>Company | >Ingredient | >NDC |
GEFITINIB drug variants not containing POVIDONE K30
Company | Ingredient | NDC |
---|---|---|
AstraZeneca Pharmaceuticals LP | gefitinib | 0310-0482 |
Teva Pharmaceuticals Inc | gefitinib | 0480-4053 |
Apotex Corp | gefitinib | 60505-4512 |
>Company | >Ingredient | >NDC |
Excipient focus: SILICON DIOXIDE
GEFITINIB drug variants containing SILICON DIOXIDE
Company | Ingredient | NDC |
---|---|---|
Apotex Corp | gefitinib | 60505-4512 |
>Company | >Ingredient | >NDC |
GEFITINIB drug variants not containing SILICON DIOXIDE
Company | Ingredient | NDC |
---|---|---|
AstraZeneca Pharmaceuticals LP | gefitinib | 0310-0482 |
Teva Pharmaceuticals Inc | gefitinib | 0480-4053 |
Ingenus Pharmaceuticals LLC | gefitinib | 50742-366 |
Qilu Pharmaceutical Co Ltd | gefitinib | 67184-0531 |
Natco Pharma USA LLC | gefitinib | 69339-168 |
>Company | >Ingredient | >NDC |
Excipient focus: SODIUM LAURYL SULFATE
GEFITINIB drug variants containing SODIUM LAURYL SULFATE
Company | Ingredient | NDC |
---|---|---|
AstraZeneca Pharmaceuticals LP | gefitinib | 0310-0482 |
Teva Pharmaceuticals Inc | gefitinib | 0480-4053 |
Ingenus Pharmaceuticals LLC | gefitinib | 50742-366 |
Qilu Pharmaceutical Co Ltd | gefitinib | 67184-0531 |
Natco Pharma USA LLC | gefitinib | 69339-168 |
>Company | >Ingredient | >NDC |
GEFITINIB drug variants not containing SODIUM LAURYL SULFATE
Company | Ingredient | NDC |
---|---|---|
Apotex Corp | gefitinib | 60505-4512 |
>Company | >Ingredient | >NDC |
Excipient focus: TALC
GEFITINIB drug variants containing TALC
Company | Ingredient | NDC |
---|---|---|
Teva Pharmaceuticals Inc | gefitinib | 0480-4053 |
Ingenus Pharmaceuticals LLC | gefitinib | 50742-366 |
Apotex Corp | gefitinib | 60505-4512 |
Qilu Pharmaceutical Co Ltd | gefitinib | 67184-0531 |
Natco Pharma USA LLC | gefitinib | 69339-168 |
>Company | >Ingredient | >NDC |
GEFITINIB drug variants not containing TALC
Company | Ingredient | NDC |
---|---|---|
AstraZeneca Pharmaceuticals LP | gefitinib | 0310-0482 |
>Company | >Ingredient | >NDC |
Excipient focus: TITANIUM DIOXIDE
GEFITINIB drug variants containing TITANIUM DIOXIDE
Company | Ingredient | NDC |
---|---|---|
AstraZeneca Pharmaceuticals LP | gefitinib | 0310-0482 |
Teva Pharmaceuticals Inc | gefitinib | 0480-4053 |
Ingenus Pharmaceuticals LLC | gefitinib | 50742-366 |
Apotex Corp | gefitinib | 60505-4512 |
Qilu Pharmaceutical Co Ltd | gefitinib | 67184-0531 |
Natco Pharma USA LLC | gefitinib | 69339-168 |
>Company | >Ingredient | >NDC |
GEFITINIB drug variants not containing TITANIUM DIOXIDE
Company | Ingredient | NDC |
---|---|---|
>Company | >Ingredient | >NDC |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.